MedTrace Logo

Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer

NCT00420732 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-05-28

No results posted yet for this study

Summary

To determine the response rate of the administration of HyperAcute-Lung Cancer Vaccine for subjects with stage IIIB or stage IV non-small cell lung cancer who have been treated with first line platinum-doublet therapy and have responded or are considered to have stable disease.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

BIOLOGICAL

HyperAcute-Lung Cancer Vaccine

300 million cells given intradermally every 3 weeks for up to a total of 12 vaccinations

Sponsors & Collaborators

  • NewLink Genetics Corporation

    lead INDUSTRY

Principal Investigators

  • Charles J. Link, Jr., M.D. · NewLink Genetics Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2012-11-30
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00420732 on ClinicalTrials.gov